
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 6 505-514, Copyright © 1998 by American Association for Cancer Research
ARTICLES |
SA Waldman, M Barber, J Pearlman, J Park, R George and SJ Parkinson
Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. waldmans@jeflin.tju.edu
In humans, guanylyl cyclase C (GCC) is expressed by mucosal cells lining the intestine, from the duodenum to the rectum, but not by extraintestinal tissues. Expression of GCC persists after mucosal cells undergo neoplastic transformation, and this protein has been identified in all primary and metastatic colorectal tumors examined to date, suggesting that GCC may be a highly specific biomarker for colorectal cancer. The utility of GCC as a diagnostic biomarker and therapeutic target is predicated, in part, on defining the variability of its expression in colorectal cancer cells. Similarly, the utility of this biomarker to define tumor burden in diagnosing, staging, and postoperative surveillance of patients is predicated on quantifying GCC expression in cancer cells in tissues and blood. The present studies examined the heterogeneity of GCC expression in eight human colorectal carcinoma cell lines in vitro representing the full spectrum of cytological differentiation. Quantification of GCC expression by ligand binding and stimulation of cGMP accumulation demonstrated that functional GCC expression is heterogeneous in different colorectal cancer cell lines. Qualitative reverse transcription (RT)-PCR demonstrated that all colorectal cancer cells examined expressed GCC mRNA. However, GCC expression varied 100-fold in different colorectal cancer cell lines, determined by a novel quantitative RT-PCR assay. Functional and molecular expressions of GCC were unrelated to the differentiation state of cancer cells. These studies suggest that GCC is heterogeneously expressed by colorectal cancer cells in vitro and suggest a role for quantitative RT-PCR analysis in the development of diagnostic tests using GCC as a biomarker for metastatic colorectal cancer.
This article has been cited by other articles:
![]() |
G. M. Pitari, J. E. Lin, F. J. Shah, W. J. Lubbe, D. S. Zuzga, P. Li, S. Schulz, and S. A. Waldman Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells Carcinogenesis, August 1, 2008; 29(8): 1601 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Pitari, T. Li, R. I. Baksh, and S. A. Waldman Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells Mol. Cancer Ther., May 1, 2006; 5(5): 1190 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Carrithers Diarrhea or colorectal cancer: Can bacterial toxins serve as a treatment for colon cancer? PNAS, March 18, 2003; 100(6): 3018 - 3020. [Full Text] [PDF] |
||||
![]() |
G. M. Pitari, L. V. Zingman, D. M. Hodgson, A. E. Alekseev, S. Kazerounian, M. Bienengraeber, G. Hajnoczky, A. Terzic, and S. A. Waldman Bacterial enterotoxins are associated with resistance to colon cancer PNAS, March 4, 2003; 100(5): 2695 - 2699. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Park, S. Schulz, J. Haaf, J. C. Kairys, and S. A. Waldman Ectopic Expression of Guanylyl Cyclase C in Adenocarcinomas of the Esophagus and Stomach Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 739 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Fava, R. Desnoyers, S. Schulz, J. Park, D. Weinberg, E. Mitchell, and S. A. Waldman Ectopic Expression of Guanylyl Cyclase C in CD34+ Progenitor Cells in Peripheral Blood J. Clin. Oncol., October 1, 2001; 19(19): 3951 - 3959. [Abstract] [Full Text] |
||||
![]() |
G. M. Pitari, M. D. Di Guglielmo, J. Park, S. Schulz, and S. A. Waldman Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells PNAS, July 3, 2001; 98(14): 7846 - 7851. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Cagir, A. Gelmann, J. Park, T. Fava, A. Tankelevitch, E. W. Bittner, E. J. Weaver, J. P. Palazzo, D. Weinberg, R. D. Fry, et al. Guanylyl Cyclase C Messenger RNA Is a Biomarker for Recurrent Stage II Colorectal Cancer Ann Intern Med, December 7, 1999; 131(11): 805 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. ZHANG, I. MANNAN, S. SCHULZ, S. J. PARKINSON, A. E. ALEKSEEV, L. A. GOMEZ, A. TERZIC, and S. A. WALDMAN Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea FASEB J, May 1, 1999; 13(8): 913 - 922. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |